Completed PHASE1 INTERVENTIONAL 4-arm NCT01833546

A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer

A Japanese Single Center, Open-label, Phase I Trial of TH-302 Given Intravenously to Subjects With Solid Tumors as Monotherapy or to Subjects With Advanced Pancreatic Cancer in Combination With Gemcitabine

Sponsor: Merck KGaA, Darmstadt, Germany

Conditions Pancreatic Cancer Solid Tumor

Interventions Evofosfamide Gemcitabine

Updated 9 times since 2017 Last updated: Mar 8, 2018 Started: Apr 18, 2013 Primary completion: Aug 31, 2015 Completion: Jan 25, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Pancreatic Cancer and Solid Tumor and is currently completed. Merck KGaA, Darmstadt, Germany leads this study, which shows 9 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jan 2019 — Jan 2021 [monthly]

Completed PHASE1
Nov 2018 — Jan 2019 [monthly]

Completed PHASE1
Jun 2018 — Nov 2018 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck KGaA, Darmstadt, Germany
Threshold Pharmaceuticals

Data source: Merck KGaA, Darmstadt, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kashiwa, Japan
• Tokyo, Japan